Table 1.
Characteristics of the randomized controlled trials included in this study.
| study | Number of cases | Control regimen (TACE) | Aidi intervention | therapeutic courses (days/cycles) | HCC staging | KPS score | Randomized method | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| T/C | M/F | Age | |||||||||
| Tan L et al. 2017 [5] | 30/32 | 39/23 | 20-70 | L-OHP+ADM+5-FU | 50 ml/d | 30 d∗2 | II, III, IV | NA | NA | ||
| Dong HT et al. 2008 [6] | 46/46 | 68/24 | 28 - 77 | HCPT+5-FU | 60 ml/d | 28 d∗2 | NA | >60 | NA | ||
| Liu GY et al. 2011 [7] | 30/28 | 40/18 | 47 | ADM+MMC+5-FU | 60 ml/d | 15 d∗4 | I, II, III | ⩾70分 | Random number table | ||
| Zhang GS et al. 2012 [8] | 47/47 | 68/26 | 29-78 | HCPT+5-FU | 100 ml/d | 28 d∗2 | II, III, IV | >60 | NA | ||
| Meng SX et al. 2008 [9] | 75/73 | 97/51 | 55.2 | THP+5-FU | 50 ml/d | 14 d∗2 | II, III, IV | >60 | NA | ||
| Ma T et al. 2005 [10] | 36/29 | 5/60 | 47 | DDP+HCPT+5-FU | 50 ml/d | 10 d∗1-2 | I, II, III | >60 | Medical record card number | ||
| Tao HY et al. 2017 [11] | 64/64 | 77/59 | 40-75 | L-OHP+EPI+5-FU | 60 ml/d | 28 d∗4 | I, II, III | >50 | NA | ||
| Yu B. 2013 [12] | 30/30 | 29/31 | 18-65 | DDP+ADM+MMC+5-FU | 50 ml/d | 60 d∗1 | NA | >60 | NA | ||
| A YXMGL et al. 2011 [13] | 54/54 | 80/28 | 28-77 | HCPT+5-FU | 60 ml/d | 21 d∗2 | II, III, IV | >60 | NA | ||
| Guo MA et al. 2016 [14] | 36/35 | 47/24 | 55.6 | ADM+MMC+5-FU | 60 ml/d | 14 d∗2 | NA | NA | NA | ||
| Yang JM et al 2006 [15] | 31/31 | 50/12 | 27 - 68 | ADM+DDP+5-FU | 50 ml/d | 15 d∗2 | NA | NA | NA | ||
| Huang J 2009 [16] | 30/30 | 51/9 | 45.1 | ADM+DDP+5-FU | 80 ml/d | 15 d∗2 | NA | 30 - 60 | NA | ||
| Yuan HS et al 2010 [17] | 21/21 | 36/6 | 28-74 | MMC+THP+5-FU | 50- 100 ml/d | 10 d∗1-2 | NA | NA | NA | ||
| Chen SC et al 2007 [18] | 32/28 | 41/49 | 36-70 | MMC+HU+5-FU | 60 ml/d | 21 d∗2 | NA | >60 | NA | ||
| Li YY et al. 2016 [19] | 26/26 | 32/20 | 21-80 | DDP+EPI+5-FU | 40-80 ml/d | 15 d∗2 | III, IV | 30 - 60 | Random number table | ||
| Yang ZJ et al. 2011 [20] | 30/30 | 53/7 | 26-69 | MMC+EPI+HCPT+5-FU | 50-100 mL | 10 d∗3 | NA | ⩾70 | Envelope method | ||
| Zheng Q et al. 2005 [21] | 48/48 | 73 /25 | 50.6 | THP+HCPT+5-FU | 50 ml | 28 d∗2 | NA | >60 | NA | ||
| Zhan GQ et al. 2010 [22] | 32/26 | 46/12 | 21-65 | MMC+HCPT+EPI+5-FU | 50 ml | 20 d∗2 | II, III | >50 | NA | ||
| Ma BQ. 2007 [23] | 60/60 | 78 /42 | 17-82 | DDP+CF+MMC+5-FU | 50 ml | 15 d∗3 | NA | ⩾60 | NA | ||
| Wang QP et al 2008 [24] | 25/23 | 37/11 | 29-68 | MMC+ADM+5-FU | 100 ml/d | 40 d | NA | NA | NA | ||